Cytek Biosciences Inc. Common Stock (CTKB)
Stock · NASDAQ · Industrials
$5.25as of 10/16/2026
Price chart
Active signals
CTKB Signal Track Record
How signals performed across all stocks →What CTKB's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | -1.4% | 46% | September 9, 2026 |
| Bollinger Band Breakdown | 26 | 0.0% | 50% | July 30, 2026 |
| Bollinger Band Breakout | 21 | -3.3% | 29% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 19 | +1.8% | 53% | September 8, 2026 |
| Any 20-session window (baseline) | -0.9% | 48% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CTKB
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approac…
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Employees
- 682
- Website
- cytekbio.com
Fundamentals
- 1-day range
- $5.3$5.56
- Market cap
- $537.23M
- P/E (trailing)
- —
- P/E (forward)
- 77.57
- EPS (trailing)
- $-0.63
- Dividend yield
- —
- Beta
- 1.14
- Avg. volume
- 1.10M
How Cytek Biosciences Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Cytek Biosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CTKBCytek Biosciences Inc. Common Stock$5.25▼ 2.96%Market cap $537.23MP/E —$3.31$6.21
- PACBPacific Biosciences of California Inc. Common Stock$1.73▼ 11.73%Market cap $361.85MP/E —$1.07$3.44
- LABStandard BioTools Inc. Common Stock$0.63▼ 4.55%Market cap $313.21MP/E 2.92$0.6251$1.72
- QTRXQuanterix Corporation Common Stock$2.87▼ 6.51%Market cap $180.42MP/E —$2.15$8.77
- SEERSeer Inc. Class A Common Stock$2.03▼ 0.49%Market cap $120.41MP/E —$1.55$2.41
- NAUTNautilus Biotechnology Inc. Common Stock$2.06▼ 4.63%Market cap $112.76MP/E —$0.8399$4.31
- RPIDRapid Micro Biosystems Inc. Class A Common Stock$0.764▼ 9.59%Market cap $96.03MP/E —$0.8087$4.94
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CTKB Cytek Biosciences Inc. Common Stock | $537.23M | — | $5.25 | ▼ 2.96% | $3.31$6.21 |
| PACB Pacific Biosciences of California Inc. Common Stock | $361.85M | — | $1.73 | ▼ 11.73% | $1.07$3.44 |
| LAB Standard BioTools Inc. Common Stock | $313.21M | 2.92 | $0.63 | ▼ 4.55% | $0.6251$1.72 |
| QTRX Quanterix Corporation Common Stock | $180.42M | — | $2.87 | ▼ 6.51% | $2.15$8.77 |
| SEER Seer Inc. Class A Common Stock | $120.41M | — | $2.03 | ▼ 0.49% | $1.55$2.41 |
| NAUT Nautilus Biotechnology Inc. Common Stock | $112.76M | — | $2.06 | ▼ 4.63% | $0.8399$4.31 |
| RPID Rapid Micro Biosystems Inc. Class A Common Stock | $96.03M | — | $0.764 | ▼ 9.59% | $0.8087$4.94 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Feuchtwang Ilan · August 10, 2026 · Grant127.1K
- Feuchtwang Ilan · August 10, 2026 · Grant241.4K
- Ming Yan · June 12, 2026 · Gift135.9K
- Vera Imper · June 10, 2026 · Option Exercise44.0K
- Vera Imper · June 10, 2026 · Grant18.3K
- Vera Imper · June 10, 2026 · Grant33.3K
- Jack Ball · June 10, 2026 · Option Exercise44.0K
- Michael Holder · June 10, 2026 · Option Exercise44.0K
- Michael Holder · June 10, 2026 · Grant18.3K
- Michael Holder · June 10, 2026 · Grant33.3K
- Glenn P. Muir · June 10, 2026 · Grant29.8K
- Glenn P. Muir · June 10, 2026 · Grant55.6K
- Richard Chin · June 10, 2026 · Grant18.3K
- Richard Chin · June 10, 2026 · Grant33.3K
- Deborah J. Neff · June 10, 2026 · Option Exercise44.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 81.71M
- Total value held
- $351.24M
- Institutional holders
- 161
- Unknown17.01M
- Unknown7.06M
- Unknown6.66M
- Unknown6.29M
- Unknown5.80M
- Unknown4.76M
- Unknown4.12M
- Unknown2.83M
- Unknown2.66M
- Unknown2.34M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Cytek spotlights spectral flow cytometry at ESCCA and ICCS conferences
Cytek Biosciences drew attention to the growing use of its spectral flow cytometry technology in clinical research at the ESCCA and ICCS conferences. The company also confirmed it will attend upcoming investor conferences. These are routine participation and awareness events rather than material business updates, with no new financial figures or product announcements disclosed. The current price sits within the stock's 52-week range of $3.28 to $6.18, below the average analyst target of $5.56.
Cytek spotlights spectral flow cytometry at ESCCA and ICCS conferences. Cytek Biosciences drew attention to the growing use of its spectral flow cytometry technology in clinical research at the ESCCA and ICCS conferences. The company also confirmed it will attend upcoming investor conferences. These are routine participation and awareness events rather than material business updates, with no new financial figures or product announcements disclosed. The current price sits within the stock's 52-week range of $3.28 to $6.18, below the average analyst target of $5.56.